Mizuho initiated coverage of Spyre Therapeutics (SYRE) with an Outperform rating and $53 price target The firm believes the company’s half-life extended monoclonal antibody pipeline as positioned to play a “significant role” in inflammatory bowel disease. The company’s more compelling opportunity is its ability to evaluate novel combinations, the analyst tells investors in a research note. It projects risk-adjusted worldwide sales of $1.7B in 2035.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics initiated with a Buy at Citi
- Buy Rating for Spyre Therapeutics Driven by Strong Stock Performance and Promising Clinical Developments
- Carvana initiated, Zscaler downgraded: Wall Street’s top analyst calls
- 3 Best Stocks to Buy Now, 12/1/2025, According to Top Analysts
- Spyre Therapeutics upgraded to Buy from Hold at JonesResearch